RE:RE:RE:RE:RE:RE:Nice deal here
This is one of my favourite yardsticks when assessing a company's prospects - whether the management team has the confidence to invest in their own future. All of the management team of PMN are significant shareholders and these are not shares that they simply gave themselves but, rather, shares that they purchased through PP and financing processes. This is even better than buying shares on the open market because the proceeds go directly to the company instead of to someone on the outside. Our management has put their own cold, hard cash on the line so by that measure you can be reassured.
A second yardstick is whether a company enjoys the confidence of outside institutional and large investors. In this case we have Michael Bigger of Bigger Capital. Obviously a more connected, savvy and successful investor than any of us minnows here - simply riding the coattails of someone such as Mr. Bigger will lead to success more often than not. Bigger is a significant shareholder in PMN. If you knew nothing about the company, the management team or the intellectual property his involvement and endorsement alone should be enough to make you click the buy button.
A third yardstick is to look at the bios and previous successes of the management team - another checkmark here. Just visit https://promisneurosciences.com/team/.
The fourth, and final, criteria is the product. PMN holds numerous patents for intellectual property associated with some of the most devastating diseases facing the human race. There is a massive unmet (so far) need and the discoveries continue - each one being patented along the way. Large pharma has been unable to meet these needs: ALS, AD and others. Each discovery, each patent shows that Dr Cashman and PMN are on the right path to solving these medical needs. According to the Alzheimers Association website the cost of this disease in 2016, just for the USA, will be 236 billion. That's one country for one year. So do a bit of math in your head and try to understand what a treatment would be worth.
After considering the above facts, ask yourself if you think PMN is worth .15 cents/share.